Effect of Short-term Motilitone Therapy on Health-related Quality of Life in PD Patients With Gastrointestinal Symptoms

Phase 4 Completed 147 enrolled Seoul National University Hospital Hanyang University · collab Korea University Guro Hospital · collab SMG-SNU Boramae Medical Center · collab Samsung Medical Center · collab Seoul Veterans Hospital · collab

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to determine whether DA-9701(Motilitone) is effective and safe for the treatment on health-related quality of life in Parkinson's disease (PD) patients with gastrointestinal symptoms.

Timeline

Start: 2016-04
Primary completion: 2018-06
Completion: 2018-12

Outcome

Met primary endpoint

paper The gastrointestinal symptom-related quality-of-life score significantly improved in the DA-9701-treated group compared with the placebo-treated group after 4weeks (adjusted P = 0.012 PMID 32761955 ↗

Publications

Choi JH, Lee JY, Cho JW, Koh SB, Yang YS, Yoo D, Shin CM, Kim HT. Double-Blind, Randomized, Placebo-Controlled Trial of DA-9701 in Parkinson's Disease: PASS-GI Study. Mov Disord. 2020 Nov;35(11):1966-1976. doi: 10.1002/mds.28219. Epub 2020 Aug 6.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	LUCORIDALINES	Unknown	30 mg	—